×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ACRS – aclaris therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ACRS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/12
06:55 am
acrs
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052
Low
Report
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052
1/6
06:59 am
acrs
Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Ra Bispecific Antibody ATI-052 Supporting Expedited Clinical Development
Low
Report
Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Ra Bispecific Antibody ATI-052 Supporting Expedited Clinical Development
12/30
04:09 pm
acrs
Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Medium
Report
Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
12/23
04:09 pm
acrs
Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Medium
Report
Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
12/19
07:04 pm
acrs
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI) [Yahoo! Finance]
Low
Report
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI) [Yahoo! Finance]
12/19
04:01 pm
acrs
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)
Low
Report
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)
11/25
08:14 am
acrs
Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
Low
Report
Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
11/25
08:00 am
acrs
Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
Low
Report
Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
Date
Time
Symbol
Company Name
Action
%Chg
11/6/2025
06:59 am
acrs
aclaris therapeutics, inc.
BEAT
Report
0.4%
aclaris therapeutics, inc.
8/7/2025
06:59 am
acrs
aclaris therapeutics, inc.
IN-LINE
Report
1.3%
aclaris therapeutics, inc.
5/8/2025
06:50 am
acrs
aclaris therapeutics, inc.
BEAT
Report
7.4%
aclaris therapeutics, inc.
2/27/2025
06:59 am
acrs
aclaris therapeutics, inc.
MISS
Report
-13.3%
aclaris therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/12
07:01 am
acrs
Form 8-K Aclaris Therapeutics, For: Jan 12
Low
Report
Form 8-K Aclaris Therapeutics, For: Jan 12
1/9
09:00 am
acrs
Form SCHEDULE 13G/A Aclaris Therapeutics, Filed by: Bonita Biotech (HK) Ltd
Low
Report
Form SCHEDULE 13G/A Aclaris Therapeutics, Filed by: Bonita Biotech (HK) Ltd
1/6
07:15 am
acrs
Form 8-K Aclaris Therapeutics, For: Jan 06
Low
Report
Form 8-K Aclaris Therapeutics, For: Jan 06
1/5
04:32 pm
acrs
Form 4 Aclaris Therapeutics, For: Jan 02 Filed by: Walker Neal
Low
Report
Form 4 Aclaris Therapeutics, For: Jan 02 Filed by: Walker Neal
1/5
04:30 pm
acrs
Form 4 Aclaris Therapeutics, For: Dec 31 Filed by: Loerop James
Low
Report
Form 4 Aclaris Therapeutics, For: Dec 31 Filed by: Loerop James
1/5
04:28 pm
acrs
Form 4 Aclaris Therapeutics, For: Dec 31 Filed by: Balthaser Kevin
Low
Report
Form 4 Aclaris Therapeutics, For: Dec 31 Filed by: Balthaser Kevin
12/4
04:51 pm
acrs
Form 4 Aclaris Therapeutics, For: Dec 02 Filed by: Davis Hugh M.
Low
Report
Form 4 Aclaris Therapeutics, For: Dec 02 Filed by: Davis Hugh M.
11/13
09:06 am
acrs
Form SCHEDULE 13G/A Aclaris Therapeutics, Filed by: Adage Capital Management, L.P.
Low
Report
Form SCHEDULE 13G/A Aclaris Therapeutics, Filed by: Adage Capital Management, L.P.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
9/16
Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2)
63.6%
11/7 Form 8-K Aclaris Therapeutics, For: Nov 07 39.3%
10/10 Aclaris Therapeutics Announces Divestiture of RHOFADE® 19.3%
1/9 Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor 17.2%
10/15 Aclaris Therapeutics Inc (NASDAQ: ACRS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 9.1%
7/9 Aclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering RHOFADE® (Oxymetazoline Hydrochloride) Cream, 1% 9.1%
12/19 Form SC 13D/A Aclaris Therapeutics, Filed by: Arkin Moshe 8.8%
9/5 Aclaris Therapeutics Inc (NASDAQ: ACRS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 8.6%
10/31 Aclaris Therapeutics to Announce Third Quarter 2019 Financial Results on November 7, 2019 8.0%
2/10 Form SC 13G/A Aclaris Therapeutics, Filed by: Man Group plc 7.9%
11/7 Form 8-K Aclaris Therapeutics, For: Nov 07 39.3%
10/10 Aclaris Therapeutics Announces Divestiture of RHOFADE® 19.3%
1/9 Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor 17.2%
10/15 Aclaris Therapeutics Inc (NASDAQ: ACRS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 9.1%
7/9 Aclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering RHOFADE® (Oxymetazoline Hydrochloride) Cream, 1% 9.1%
12/19 Form SC 13D/A Aclaris Therapeutics, Filed by: Arkin Moshe 8.8%
9/5 Aclaris Therapeutics Inc (NASDAQ: ACRS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 8.6%
10/31 Aclaris Therapeutics to Announce Third Quarter 2019 Financial Results on November 7, 2019 8.0%
2/10 Form SC 13G/A Aclaris Therapeutics, Filed by: Man Group plc 7.9%
TOP News Decliners
6/26
Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-502 Topical in Patients with Alopecia Areata Did Not Meet Endpoints
-52.1%
7/30 Glancy Prongay & Murray LLP Files Securities Class Action on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS) -39.0%
2/25 Form 10-K Aclaris Therapeutics, For: Dec 31 -22.2%
8/8 Form 10-Q Aclaris Therapeutics, For: Jun 30 -13.5%
9/25 DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Aclaris Therapeutics, Inc. (NASDAQ: ACRS) and Encourages Aclaris Investors to Contact the Firm -11.7%
11/21 Form 8-K Aclaris Therapeutics, For: Nov 21 -11.2%
3/31 Form 8-K Aclaris Therapeutics, For: Mar 30 -11.1%
9/17 Aclaris Therapeutics to Hold R&D Day -10.9%
3/6 Form SC 13G Aclaris Therapeutics, Filed by: Samsara BioCapital, L.P. -10.8%
5/8 Form 10-Q Aclaris Therapeutics, For: Mar 31 -10.0%
7/30 Glancy Prongay & Murray LLP Files Securities Class Action on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS) -39.0%
2/25 Form 10-K Aclaris Therapeutics, For: Dec 31 -22.2%
8/8 Form 10-Q Aclaris Therapeutics, For: Jun 30 -13.5%
9/25 DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Aclaris Therapeutics, Inc. (NASDAQ: ACRS) and Encourages Aclaris Investors to Contact the Firm -11.7%
11/21 Form 8-K Aclaris Therapeutics, For: Nov 21 -11.2%
3/31 Form 8-K Aclaris Therapeutics, For: Mar 30 -11.1%
9/17 Aclaris Therapeutics to Hold R&D Day -10.9%
3/6 Form SC 13G Aclaris Therapeutics, Filed by: Samsara BioCapital, L.P. -10.8%
5/8 Form 10-Q Aclaris Therapeutics, For: Mar 31 -10.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: